OXFORD VACMEDIX
Oxford Vacmedix was established in 2012 as a spinout from Oxford University. Its aim is to develop therapeutic agents for the treatment of cancer based on the invention of Dr Shisong Jiang - Recombinant Overlapping Peptides (ROP). These agents are an exciting new way to deliver immunotherapy which is now a major focus in the treatment of cancer, making it easier to deliver, more effective and much more economical. Immunotherapy is effective by activating the immune system to attack tumours directly thus reducing the need for invasive treatments such as chemo and radiotherapy.
OXFORD VACMEDIX
Industry:
Health Care Pharmaceutical Therapeutics
Founded:
2012-01-01
Address:
Oxford, Oxfordshire, United Kingdom
Country:
United Kingdom
Website Url:
http://www.oxfordvacmedix.com
Total Employee:
1+
Status:
Active
Total Funding:
12.5 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Font API Google Analytics Apple Mobile Web Clips Icon Google Tag Manager WordPress Font Awesome
Similar Organizations
Affimed
Affimed Therapeutics is focused on developing recombinant antibody therapeutics for the treatment of cancer and other diseases.
Ennar Pharma
Development of medicines for the treatment of psoriasis.
Current Employees Featured
Shisong Jiang Chief Scientific Officer and Founder @ Oxford Vacmedix
Chief Scientific Officer and Founder
William Finch CEO @ Oxford Vacmedix
CEO
Founder
Investors List
Cancer Rop
Cancer Rop investment in Series A - Oxford Vacmedix
Oxford University Innovation
Oxford University Innovation investment in Seed Round - Oxford Vacmedix
Official Site Inspections
http://www.oxfordvacmedix.com
- Host name: 92.205.145.103
- IP address: 92.205.145.103
- Location: Germany
- Latitude: 51.4476
- Longitude: 7.0122
- Timezone: Europe/Berlin
More informations about "Oxford Vacmedix"
About us - Oxford Vacmedix
Www.oxfordvacmedix.com; enquiries@oxfordvacmedix.com +44 (0) 1865 784074; Oxford Vacmedix UK Limited, The Magdalen Centre, The Oxford Science Park, Oxford OX4 4GA; …See details»
Oxford Vacmedix - Crunchbase Company Profile
Contact Email Enquiries@oxfordvacmedix.com Oxford Vacmedix was established in 2012 as a spinout from Oxford University. Its aim is to develop therapeutic agents for the treatment of cancer based on the invention of Dr Shisong Jiang …See details»
Cancer vaccine firm Oxford Vacmedix announces collaboration …
Https://www.oxfordvacmedix.com _____ About Oxford Vacmedix Oxford Vacmedix UK Ltd, based on the Oxford Science Park, UK, is a bio-pharma company that utilizes the novel proprietary …See details»
Oxford Vacmedix - PitchBook
Oxford Vacmedix General Information Description. Operator of a therapeutic agents development company intended to deliver immunotherapy for cancer treatment. The company's therapeutic …See details»
Oxford Vacmedix - Products, Competitors, Financials, Employees ...
Oxfordvacmedix.com. Overview & Products; Financials; People; Founded Year 2012. Stage Series A | Alive. Total Raised $13.9M. Last Raised $12.5M | 7 yrs ago. About Oxford …See details»
Oxford Vacmedix appoints Dr Nam Park as Chief Business Officer
Jan 16, 2025 The appointment of Dr Nam Park as Chief Business Officer brings further expertise in venture financing and capital markets to Oxford Vacmedix. Oxford, UK – 16th January 2025 …See details»
CEO Spotlight: Tony Coombs, Executive Chairman, Oxford VacMedix
12th October 2023. For the latest in our CEO Spotlight series, we caught up with Dr Tony Coombs, Executive Chairman of Oxford VacMedix - a spinout company making waves in the …See details»
Oxford Vacmedix - Craft
Oxford Vacmedix is a biotech company developing therapeutic agents for the treatment of cancer based on the recombinant overlapping peptides. These agents help to deliver immunotherapy …See details»
Oxford Vacmedix - VentureRadar
Website: https://www.oxfordvacmedix.com/ Develops therapeutic agents for cancer treatment using Recombinant Overlapping Peptides (ROP), enhancing immunotherapy ...See details»
Cancer vaccine firm Oxford Vacmedix announces ... - CHAIN Biotech
T: +44 (0) 1865 742087 | M: +44(0)7769 903711 | E: wfinch@oxfordvacmedix.com https://www.oxfordvacmedix.com. About Oxford Vacmedix. Oxford Vacmedix UK Ltd, based …See details»
Oxford Vacmedix Innovates Cancer Treatment with …
Jul 15, 2024 Oxford Vacmedix's work exemplifies the potential for therapeutic vaccines to transform cancer care, offering targeted, effective, and less invasive treatment options that …See details»
Oxford Vacmedix - VentureRadar
Similar Companies: ForMune Spain Privately Held ForMune is a Spain-based developer of molecules for subsequent license to pharmaceutical companies and/or marketing. Set up as a …See details»
Oxford Vacmedix licenses OVM-200 to Dx&Vx
Dec 13, 2024 For more information: https://www.oxfordvacmedix.com. About Dx&Vx. Dx&Vx develops and researches novel biotechnology solutions for healthcare. The company offers …See details»
Oxford Vacmedix Ltd.: harnessing the power of immunotherapy to …
Organization (CMO) in Europe. Additionally, using ROPs as diagnostic reagents, ... www.oxfordvacmedix.com Figure 1: Antigen presentation of ROP. MHC, major …See details»
Oxford Vacmedix UK Ltd. (Oxford Vacmedix UK Ltd.) - 药物管线_专 …
ENDS For more information or to express an interest in investing in Series B please contact: William Finch, CEO, Oxford Vacmedix T: +44 (0)1865 742087 | M: +44(0)7769 903711 | E: …See details»
Oxford Vacmedix Ltd.: harnessing the power of immunotherapy to …
A new platform built around recombinant overlapping peptides (ROPs) promises quicker and cheaper production of more effective therapeutic vaccines and diagnostics for cancer and viral …See details»
Oxford Vacmedix Wins €10M in Funding for Cancer Vaccines
Mar 7, 2018 White blood cells attacking a cancer cell. These developments highlight the innovative approaches to vaccines coming from Oxford spin-outs. In January, Vaccitech raised …See details»
Innovate UK award to OVM for clinical development of OVM-200
Jan 9, 2025 For more information: https://www.oxfordvacmedix.com. About Innovate UK. Innovate UK is the UK’s innovation agency helping UK businesses to grow through innovation. …See details»
Identifying fake COVID-19 vaccines by analysing vial labels and …
Jan 31, 2025 The World Health Organization (WHO) estimates that 10.5% of medicines worldwide in low- and middle-income countries are substandard or are falsified (i.e. fake) …See details»
Oxford Vacmedix announces lead investment for Series B fund
Nov 6, 2024 For more information: https://www.oxfordvacmedix.com. About Dx&Vx. Dx&Vx develops and researches novel biotechnology solutions for healthcare. The company offers …See details»